Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients

Media & Investor Release   Roche and Atea partner to jointly develop AT-527, an orally administered direct-acting antiviral (DAA) currently in Phase 2 clinical trials AT-527 has the potential to be the first novel oral antiviral to treat COVID-19 patients outside the hospital setting as well as in the hospital and may also be used in post-exposure